Rabbit Anti-Obinutuzumab polyclonal antibody

Antibody Isotype

IgG

Immunogen

Obinutuzumab

Conjugate

Application Notes

Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Recommended Working Concentration: 0.005-1 μg/ml

General Notes

Suitable for use in pharmacokinetic (PK) assay. Other applications have not been tested but use in such assays should not necessarily be excluded.
This antibody serves as an excellent positive control for Obinutuzumab immunogenicity (ADA) assays.
Obinutuzumab is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It was approved under the trade name Gazyva by the US FDA in 2013, and as Gazyvaro by the EMA in Europe, for the treatment of chronic lymphocytic leukemia in combination with chemotherapy in treatment-naive patients, and as a second line treatment for follicular lymphoma. Obinutuzumab is a fully humanized monoclonal antibody that binds to an epitope on CD20 that partially overlaps with the epitope recognized by rituximab. Obinutuzumab binds to CD20 on B cells and causes these cells to be destroyed by engaging the adaptive immune system, directly activating intracellular apoptosis pathways, and activating the complement system.

Alternative Names

Rabbit polyclonal antibody to Gazyva; Afutuzumab; Obinutuzumab; GA 101